Conference item
ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
- Abstract:
-
Background: In LAPC, additional benefit of CRT over chemotherapy is uncertain. Optimising local therapy for a subset that never develops distant disease may prolong survival. Nelfinavir is thought to enhance radiosensitivity through hypoxia reduction by increasing tumour blood flow. Methods: A non-randomised, single centre phase II study, in FDG-PET-selectedpatients withhistologically proven LAPC. CRT consisted of: nelfinavir 1250 mg bd (days -3 to 45); gemcitabine 300 mg/m2 & cisplatin 3...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 113.8KB, Terms of use)
-
- Publisher copy:
- 10.1200/jco.2015.33.15_suppl.e15279
Authors
Bibliographic Details
- Publisher:
- American Society of Clinical Oncology
- Host title:
- Journal of Clinical Oncology
- Journal:
- Journal of Clinical Oncology More from this journal
- Volume:
- 33
- Issue:
- 15 suppl
- Publication date:
- 2017-01-31
- DOI:
- EISSN:
-
1527-7755
- ISSN:
-
0732-183X
Item Description
- Keywords:
- Pubs id:
-
pubs:539727
- UUID:
-
uuid:36b83003-b251-4b3a-912a-809df62a09d9
- Local pid:
-
pubs:539727
- Source identifiers:
-
539727
- Deposit date:
-
2017-01-03
Terms of use
- Copyright date:
- 2017
- Notes:
- This is the Accepted Manuscript version of the article. The final version is available online from American Society of Clinical Oncology at: https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.e15279
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record